Collplant biotechnologies provides a corporate update

-  additional patent granted for photocurable dermal filler-  update on abbvie dermal filler program and achievement of contingent payment-  plan for cost reductions in place to extend cash runway rehovot, israel , feb. 12, 2025 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), or 'collplant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update.   photocurable dermal filler program: additional patent granted collplant today announced it has been granted u.s. patent no.
CLGN Ratings Summary
CLGN Quant Ranking